XOMA news

XOMA Royalty Holdings completed its merger with XOMA Royalty Corporation on July 14. The transaction concluded with the cessation of common stock trading the previous day.

Ligand Pharmaceuticals completed the acquisition of XOMA Royalty for $39.00 per share following the deal's closing. The transaction includes a contingent value right for pending litigation proceeds.

XOMA Royalty Corporation declared quarterly dividends on its Series A and Series B Preferred Stock, with redemption of all outstanding preferred shares at $25 per share on July 14, 2026. The redemption is tied to the pending merger with Ligand Pharmaceuticals, with CVR distribution record date set f…

XOMA Royalty Corporation amended its bylaws to opt out of Nevada acquiring company statutes and designate Nevada courts as the exclusive forum for internal disputes, while federal courts handle federal securities claims. The amendments limit shareholder litigation venues and reduce exposure to acqui…